Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 16h05 HE
|
Windtree Therapeutics
WARRINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
23 août 2022 08h00 HE
|
Windtree Therapeutics
Windtree may receive up to $78.9 million in development, regulatory and commercial milestones plus low double digit royaltiesDevelopment and all other costs to be assumed by Lee’s Pharmaceutical and...
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
11 août 2022 16h05 HE
|
Windtree Therapeutics
WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value
29 juin 2022 08h00 HE
|
Windtree Therapeutics
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM:...
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid
23 mai 2022 10h12 HE
|
Windtree Therapeutics
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also...
Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock
16 mai 2022 07h00 HE
|
Windtree Therapeutics
WARRINGTON, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
05 mai 2022 16h05 HE
|
Windtree Therapeutics
Announced positive topline results from Phase 2 SEISMiC study of istaroxime in early cardiogenic shock Late-breaker presentation of additional SEISMiC study results at the European Society of...
Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference
20 avr. 2022 16h05 HE
|
Windtree Therapeutics
WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock
20 avr. 2022 07h00 HE
|
Windtree Therapeutics
WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference
31 mars 2022 16h05 HE
|
Windtree Therapeutics
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and...